Please login to the form below

Not currently logged in
Email:
Password:

EUSA founder joins Oxford BioTherapeutics as chairman

Bryan Morton has rich experience in oncology

Oxford Biotherapeutics Bryan MortonOncology-focused biotech Oxford BioTherapeutics has appointed industry veteran Bryan Morton as non-executive chairman.

Morton has 30 years' experience in the life sciences industry, including founding and serving as CEO of oncology specialist EUSA Pharma. This company was later sold to Jazz Pharma in 2012 for $700m.

Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.

In addition to his entrepreneurial activities, Morton served as president of Convatec EMEA and spent more than 20 years in various roles at Merck & Co.

“His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs,” said Christian Rohlff, CEO and founder of Oxford BioTherapeutics.

28th June 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics